CLLK.F Stock Overview
Operates as a bioconvergence company in North America, Europe, Asia, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
BICO Group AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr4.03 |
| 52 Week High | kr6.90 |
| 52 Week Low | kr2.28 |
| Beta | 2.33 |
| 1 Month Change | -4.05% |
| 3 Month Change | -12.39% |
| 1 Year Change | -24.53% |
| 3 Year Change | -91.43% |
| 5 Year Change | -87.00% |
| Change since IPO | -71.58% |
Recent News & Updates
Recent updates
Shareholder Returns
| CLLK.F | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | 5.9% | 3.3% | 1.6% |
| 1Y | -24.5% | 10.2% | 26.1% |
Return vs Industry: CLLK.F underperformed the US Life Sciences industry which returned 11.1% over the past year.
Return vs Market: CLLK.F underperformed the US Market which returned 26.8% over the past year.
Price Volatility
| CLLK.F volatility | |
|---|---|
| CLLK.F Average Weekly Movement | n/a |
| Life Sciences Industry Average Movement | 6.9% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: CLLK.F's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine CLLK.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 880 | Maria Forss | www.bico.com |
BICO Group AB (publ) operates as a bioconvergence company in North America, Europe, Asia, and internationally. It operates through three segments: Bioprinting, Biosciences, and Bioautomation. The Bioprinting segment offers products, solutions, and services that enable proliferation of 3D cell culture and 3D printing.
BICO Group AB (publ) Fundamentals Summary
| CLLK.F fundamental statistics | |
|---|---|
| Market cap | US$292.59m |
| Earnings (TTM) | -US$154.21m |
| Revenue (TTM) | US$226.87m |
1.4x
P/S Ratio-2.0x
P/E RatioIs CLLK.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CLLK.F income statement (TTM) | |
|---|---|
| Revenue | kr2.43b |
| Cost of Revenue | kr716.50m |
| Gross Profit | kr1.71b |
| Other Expenses | kr3.36b |
| Earnings | -kr1.65b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 20, 2024
| Earnings per share (EPS) | -23.37 |
| Gross Margin | 70.47% |
| Net Profit Margin | -67.97% |
| Debt/Equity Ratio | 47.1% |
How did CLLK.F perform over the long term?
See historical performance and comparison